Genmab A/S (NASDAQ:GMAB) Shares Gap Up – Time to Buy?

Genmab A/S (NASDAQ:GMAB)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $19.06, but opened at $19.73. Genmab A/S shares last traded at $19.76, with a volume of 304,550 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GMAB. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, Truist Financial reduced their price target on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Trading Up 2.7 %

The stock has a market cap of $13.33 billion, a price-to-earnings ratio of 11.57, a PEG ratio of 2.65 and a beta of 0.98. The firm has a fifty day simple moving average of $20.91 and a 200 day simple moving average of $21.97.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, equities analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. lifted its position in shares of Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after buying an additional 12,654 shares during the period. Cerity Partners LLC raised its stake in Genmab A/S by 14.6% during the third quarter. Cerity Partners LLC now owns 48,003 shares of the company’s stock worth $1,170,000 after acquiring an additional 6,103 shares in the last quarter. FMR LLC lifted its holdings in shares of Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after acquiring an additional 33,076 shares during the period. Verition Fund Management LLC acquired a new stake in shares of Genmab A/S in the 3rd quarter valued at $709,000. Finally, HighTower Advisors LLC bought a new stake in shares of Genmab A/S in the 3rd quarter worth about $273,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.